Abstract
Serum levels of β-amyloid (A) peptides may represent an early biomarker in the diagnosis of Alzheimer’s disease (AD). In the present study, we investigated the temporal kinetic changes in the levels of serum Aβ 1-42 and 40 in an amyloid precursor protein (APP)/presenilin (PS)1 double transgenic mouse model of AD. Serum Aβ peptide levels in 2-, 3-, 6-, 9- and 18-month old, and liver Aβ 1-40 level in 6-month old mice were measured using enzyme-linked immunosorbent assay (ELISA) kits. Results revealed that serum Aβ levels peaked in 3-month old transgenic mice, and the Aβ level in non-transgenic and transgenic mice is comparable in liver. Compared to the 6-month old transgenic mice, Congo red staining showed that the 3-month old transgenic mice had minimum brain Aβ plaques, corresponding to the early stage of Alzheimer-like plaque pathology, and confocal microscope images showed that the deposition of Aβ in their cerebral vessels was minimal. Furthermore, results of the water maze test, showed that memory was normal for the 3- month old transgenic mice when compared to age-matched non-transgenic mice. These results suggest that serum Aβ peptide levels may be peaked during the early stage of AD. Monitoring serum Aβ peptide levels in the potential AD population may provide an early diagnosis of AD prior to the appearance of clinical symptoms.
Keywords: APP/PS1 double transgenic mouse model, serum, -amyloid, Alzheimer’s disease, plaque, memory.
Current Alzheimer Research
Title:Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model
Volume: 10 Issue: 9
Author(s): Jue He, Jin-Ping Qiao, Shenghua Zhu, Mengzhou Xue, Wenwu Chen, Xinchun Wang, Adrien Tempier, Qingjun Huang, Jiming Kong and Xin-Min Li
Affiliation:
Keywords: APP/PS1 double transgenic mouse model, serum, -amyloid, Alzheimer’s disease, plaque, memory.
Abstract: Serum levels of β-amyloid (A) peptides may represent an early biomarker in the diagnosis of Alzheimer’s disease (AD). In the present study, we investigated the temporal kinetic changes in the levels of serum Aβ 1-42 and 40 in an amyloid precursor protein (APP)/presenilin (PS)1 double transgenic mouse model of AD. Serum Aβ peptide levels in 2-, 3-, 6-, 9- and 18-month old, and liver Aβ 1-40 level in 6-month old mice were measured using enzyme-linked immunosorbent assay (ELISA) kits. Results revealed that serum Aβ levels peaked in 3-month old transgenic mice, and the Aβ level in non-transgenic and transgenic mice is comparable in liver. Compared to the 6-month old transgenic mice, Congo red staining showed that the 3-month old transgenic mice had minimum brain Aβ plaques, corresponding to the early stage of Alzheimer-like plaque pathology, and confocal microscope images showed that the deposition of Aβ in their cerebral vessels was minimal. Furthermore, results of the water maze test, showed that memory was normal for the 3- month old transgenic mice when compared to age-matched non-transgenic mice. These results suggest that serum Aβ peptide levels may be peaked during the early stage of AD. Monitoring serum Aβ peptide levels in the potential AD population may provide an early diagnosis of AD prior to the appearance of clinical symptoms.
Export Options
About this article
Cite this article as:
He Jue, Qiao Jin-Ping, Zhu Shenghua, Xue Mengzhou, Chen Wenwu, Wang Xinchun, Tempier Adrien, Huang Qingjun, Kong Jiming and Li Xin-Min, Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model, Current Alzheimer Research 2013; 10 (9) . https://dx.doi.org/10.2174/15672050113106660159
DOI https://dx.doi.org/10.2174/15672050113106660159 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine Microglia Activation Precedes the Anti-Opioid BDNF and NMDA Receptor Mechanisms Underlying Morphine Analgesic Tolerance
Current Pharmaceutical Design Determining Serum Levels of IL-10 and IL-17 in Patients with Low Back Pain Caused by Lumbar Disc Degeneration
Infectious Disorders - Drug Targets Neurodegenerative Diseases Associated with Mitochondrial DNA Mutations
Current Pharmaceutical Design Single Vial Kit Formulation of Technetium-99m-L,L -Ethylene Dicysteine: Its Characterisation, Biodistribution and Comparison with Commercially Available 99mTc-L, L-EC Kits
Current Radiopharmaceuticals 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets Peptide-based Vaccines in the Treatment of Specific Allergy
Current Drug Targets - Inflammation & Allergy Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Use of Caffeine and Nicotine in People with Schizophrenia
Current Drug Abuse Reviews Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes
Current Topics in Medicinal Chemistry Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Chromones and their Derivatives as Radical Scavengers: A Remedy for Cell Impairment
Current Topics in Medicinal Chemistry Notch Signaling in the Central Nervous System with Special Reference to its Expression in Microglia
CNS & Neurological Disorders - Drug Targets Carbon Based Sample Supports and Matrices for Laser Desorption/Ionization Mass Spectrometry
Recent Patents on Nanotechnology